Connect with us

Company News

Acquisition of Abcam by Danaher approved by HC

Abcam plc entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation for $24.00 per share in cash (the ‘Transaction’), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).

Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.

Closing of the Transaction will occur and the Scheme will become effective upon the Court Order being delivered to the Registrar of Companies, which is expected to occur on December 6, 2023, as previously announced. The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.

Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!